Value
7.5/10data confidence 67%| Component | Sub-score |
|---|---|
| P/E | 10.0 |
| P/S | 5.8 |
| EV/EBITDA | 0.0 |
| Analyst target | 9.0 |
- ▸Attractively valued
APMD · Why this verdict
Why Apnimed (APMD) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.8/10
ConfidenceMEDIUM
MacroRISK_OFF
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Declining revenue: -29%, with operating margin scoring 0.0 and a weak Piotroski F-Score of 3/9, shows the business is not yet self-funding. Growth breakdown | Quarterly revenue should stabilize above the June 2026 level of $12.1M and Piotroski should improve above 5/9. | →Stable |
| CounterBiotech revenue is lumpy and milestone-driven (quarterly figures swing between $3.1M and $84.8M), so a decline may be timing rather than structural. | ||
At $21.51 the stock sits 98.9% below its $42.78 analyst-derived target, with an asymmetry ratio of 6.59 and attractive valuation scores. Upside pct | Price should move toward the $42.78 target if clinical and commercial milestones land over the next 12 months. | →Stable |
| CounterBiotech analyst targets assume clinical success; a binary trial failure would invalidate the target, and the engine still recommends avoiding the position. | ||
Positive insider activity: 2 insider buys and net +325,000 shares in 90 days produce a bullish insider signal. Insider | Insider net buying should continue or hold, with no net selling in the next two quarters. | →Stable |
| CounterInsider buying scored on share counts without dollar value is a weak signal, and its confidence is only 0.25, so it may not reflect conviction. | ||
Momentum failed its gate at 4.0 (below the engine's 4.5 threshold) with the price near the low end of its 52-week range, though rising OBV shows volume accumulation. Engine gate (failed) | Momentum should rise above 4.5 as RSI and moving-average positioning recover. | →Stable |
| CounterRising OBV can mask continued weakness in price, and a 52-week position score of 2.2 shows the stock still in a downtrend. | ||
The latest quarter missed (EPS -0.42 vs -0.34 estimate, -22.5% surprise) and a leverage penalty applies (D/E 1.2), weakening the overall score to 4.8. Bear case | The next report on 2026-11-11 should show EPS at or above estimate and debt-to-equity should not rise. | ↓Deteriorating |
| CounterLoss-making biotechs routinely miss on cost timing; with one quarter of history the miss is a thin basis for a thesis, and current ratio scores 7.8. | ||
Declining revenue: -29%, with operating margin scoring 0.0 and a weak Piotroski F-Score of 3/9, shows the business is not yet self-funding.
→StableGrowth breakdown
- Expectation
- Quarterly revenue should stabilize above the June 2026 level of $12.1M and Piotroski should improve above 5/9.
CounterBiotech revenue is lumpy and milestone-driven (quarterly figures swing between $3.1M and $84.8M), so a decline may be timing rather than structural.
At $21.51 the stock sits 98.9% below its $42.78 analyst-derived target, with an asymmetry ratio of 6.59 and attractive valuation scores.
→StableUpside pct
- Expectation
- Price should move toward the $42.78 target if clinical and commercial milestones land over the next 12 months.
CounterBiotech analyst targets assume clinical success; a binary trial failure would invalidate the target, and the engine still recommends avoiding the position.
Positive insider activity: 2 insider buys and net +325,000 shares in 90 days produce a bullish insider signal.
→StableInsider
- Expectation
- Insider net buying should continue or hold, with no net selling in the next two quarters.
CounterInsider buying scored on share counts without dollar value is a weak signal, and its confidence is only 0.25, so it may not reflect conviction.
Momentum failed its gate at 4.0 (below the engine's 4.5 threshold) with the price near the low end of its 52-week range, though rising OBV shows volume accumulation.
→StableEngine gate (failed)
- Expectation
- Momentum should rise above 4.5 as RSI and moving-average positioning recover.
CounterRising OBV can mask continued weakness in price, and a 52-week position score of 2.2 shows the stock still in a downtrend.
The latest quarter missed (EPS -0.42 vs -0.34 estimate, -22.5% surprise) and a leverage penalty applies (D/E 1.2), weakening the overall score to 4.8.
↓DeterioratingBear case
- Expectation
- The next report on 2026-11-11 should show EPS at or above estimate and debt-to-equity should not rise.
CounterLoss-making biotechs routinely miss on cost timing; with one quarter of history the miss is a thin basis for a thesis, and current ratio scores 7.8.
Per-dimension breakdown
Quality
5.2/10data confidence 71%| Component | Sub-score |
|---|---|
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Current ratio | 7.8 |
| Moat | 4.8 |
| Piotroski F | 3.3 |
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 3/9
Growth
0.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 0.0 |
- ▸Declining revenue: -29%
Momentum
1.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.5 |
| MACD | 1.4 |
| OBV | 1.0 |
| MA position | 2.5 |
| Volume | 0.0 |
- ▸Volume distribution (falling OBV)
Sentiment
7.2/10data confidence 67%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
- ▸Analyst upside: 183%
Insider
8.5/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 9.0 |
| insider conviction | 8.0 |
- ▸Heavy insider buying — $5,200,000 (0.685% of mkt cap)
Peer rank
5.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 7.9 |
| quality rank | 10.0 |
| growth rank | 2.8 |
- ▸Attractive P/E vs peers
- ▸Best-in-class margins
Technical
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 7.7 |
| support resistance | 9.4 |
| 52w position | 0.1 |
Risk (lower is worse)
4.0/10data confidence 60%| Component | Sub-score |
|---|---|
| days to cover | 7.7 |
| volatility | 0.0 |
| debt equity | 4.4 |
Catalyst
1.7/10data confidence 75%| Component | Sub-score |
|---|---|
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (7)
- ASYMMETRY:9.4>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:26d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:1.7<4.5
Warning (0)
none
Reward-to-Risk
9.39
Upside
+140.9%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.8B) below institutional reach
SuitabilitySpeculative — Drawdown -50% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The F-path SELL output reflects an overall score of 4.3 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Insider at 8.5) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( MOMENTUM:1.7<4.5) reinforce the read. Current asymmetry R:R is 9.39 — supplementary context, not the trigger for this path.
The strongest dimensions are Insider at 8.5, Value at 7.5, and Sentiment at 7.2; the weakest are Growth at 0.0, Catalyst at 1.7, and Momentum at 1.7. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 9.39 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Large Analyst Upside Gap
Trip ifAnalyst-derived upside falls below 20% from the current 98.9%.
- P2Insider Accumulation
Trip ifNet insider shares exceeds 0 sold (net selling above 100,000 shares) over a 90 day window from current +325,000 bought.
- P3Declining Revenue Weak Quality
Trip ifQuarterly revenue falls below $5M from the June 2026 level of $12.1M.
- P4Momentum Gate Failure
Trip ifMomentum score stays below 4.0 for 2 consecutive quarters.
- P5Earnings Miss And Leverage
Trip ifDebt-to-equity exceeds 2.0 from current 1.2.